Last reviewed · How we verify

Revance Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Revance Therapeutics, Inc. pipeline: 2 marketed, 0 filed, 1 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DAXXIFY DAXXIFY marketed Other
DAXXIFY DAXIBOTULINUMTOXINA-LANM marketed Acetylcholine Release Inhibitor [EPC] Other
DaxibotulinumtoxinA for injection DaxibotulinumtoxinA for injection phase 3 Botulinum toxin SNARE complex (acetylcholine release machinery) Aesthetics, Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 2 shared drug classes
  2. Huons Co., Ltd. · 2 shared drug classes
  3. Galderma R&D · 2 shared drug classes
  4. AbbVie · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Beth Israel Deaconess Medical Center · 1 shared drug class
  7. Amir Moradi MD, MBA · 1 shared drug class
  8. BioActive Nutritional, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Revance Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Revance Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/revance-therapeutics-inc. Accessed 2026-05-16.

Related